Abstract
Since July 2012, much EU pharmacovigilance regulation has been published so an outsider might rationally conclude that it would be easy to define what ‘best safety practices are’ now. However, what constitutes the global ‘best practice’ and whether we have achieved a consensus depends on your point of view within the system both hierarchically and geographically. As of 2012, it seems the harm from medicines in the EU has serious public health implications as the European Medicines Agency (EMA) repeatedly stated the following to justify revision of the pharmacovigilance (PV) legislation [1]:.
Cite
CITATION STYLE
Edwards, B. (2016). Best safety practices now and in the future. In Pharmacovigilance: Critique and Ways Forward (pp. 35–48). Springer International Publishing. https://doi.org/10.1007/978-3-319-40400-4_5
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
